BioSante Pharmaceuticals, Inc.
BioSante Pharmaceuticals LibiGelŪ Safety Study to Continue Following Review by External Executive Committee
Published in Medical Letter on the CDC and FDA, July 5th, 2009
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), is pleased to announce that based upon a review of study conduct and blinded data from the LibiGel Phase III Cardiovascular and Breast Cancer Safety Study, the LibiGel Safety Study External Executive Committee has recommended continuation of the LibiGel Phase III clinical program. A very low cardiovascular event rate has occurred thus far in the LibiGel Phase III clinical studies.
"Based on the trial data to date, we are confident that the LibiGel Cardiovascular and Breast Cancer Safety Study should continue to enroll new subjects and maintain treatment of those subjects already randomized to therapy. At this point, we feel...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- American Type Culture Collection ATCC
ATCC SDO Releases First Standardized Consensus Protocol - Drug Resistance
Research from L. Charneski and co-authors provides new data about drug resistance - Environmental Health
New Bisphenol a Study Is of Very Limited Relevance to Human Health - Gas Chromatography
Study findings from University of Massachusetts provide new insights into gas chromatography - Influenza
New data from S. Bolotin et al illuminate research in influenza - Life Sciences
New findings reported from A. Rivkin and co-authors describe advances in life sciences - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
